Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the ketolide telithromycin: Results from the PROTEKT surveillance study (1999-2000)

被引:13
作者
Reinert, RR
Rodloff, AC
Halle, E
Baer, W
Beyreiss, B
Seifert, H
Wichelhaus, TA
Maass, M
Mehl, M
机构
[1] Univ Hosp, Inst Med Microbiol, Natl Reference Ctr Streptococci, DE-52057 Aachen, Germany
[2] Univ Leipzig, Inst Med Microbiol & Epidemiol Infect, Leipzig, Germany
[3] Charite, Inst Microbiol & Hyg, Berlin, Germany
[4] Carl Thiem Clin, Inst Med Microbiol, Cottbus, Germany
[5] Univ Cologne, Inst Med Microbiol Immunol & Hyg, Cologne, Germany
[6] Univ Frankfurt Hosp, Inst Med Microbiol, Frankfurt, Germany
[7] Med Univ Lubeck, Inst Med Microbiol & Hyg, D-23538 Lubeck, Germany
[8] Helios Hosp, Inst Infectiol & Microbiol, Berlin, Germany
关键词
PROTEKT; Germany; antimicrobial resistance; respiratory tract pathogens;
D O I
10.1159/000077889
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin (PROTEKT) longitudinal global surveillance study examines the antibacterial susceptibility of community-acquired respiratory pathogens. Methods and Results: Data from isolates collected in Germany in 1999-2000 in the PROTEKT study show that 8.3% of pneumococcal isolates (n=325) had reduced susceptibility to penicillin and 2.2% were fully resistant. Erythromycin resistance was 15.7% overall and particularly high in Leipzig (31.6%). All penicillin- and erythromycin-resistant strains were inhibited by telithromycin (MICless than or equal to0.5 mg/l) and linezolid (MICless than or equal to2 mg/l). beta-Lactamase was produced by 3.2% of Haemophilus influenzae (9/284) and 89.5% of Moraxella catarrhalis strains (111/124). All Streptococcus pyogenes isolates (n=87) were susceptible to penicillin, although 9.2% were resistant to macrolides. Conclusions: Penicillin resistance in Germany remains low; however, the prevalence of antimicrobial resistance among common respiratory pathogens is rising, particularly against macrolides. Continued surveillance is necessary to guide optimal empirical therapy, and new antimicrobials, like telithromycin, need to be developed with improved potency against target pathogens and low propensity for the development of resistance. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:143 / 151
页数:9
相关论文
共 28 条
[11]  
Felmingham D, 2001, CLIN MICROBIOL INFEC, V7, P2, DOI 10.1046/j.1469-0691.2001.0070s3002.x
[12]   Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain:: Update (1990 to 1996) [J].
Fenoll, A ;
Jado, I ;
Vicioso, D ;
Pérez, A ;
Casal, J .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (12) :3447-3454
[13]  
Geslin R, 1998, PRESSE MED, V27, P21
[14]   Streptococcus pneunoniae resistance to erythromycin and penicillin in relation to macrolide and β-lactam consumption in Spain (1979-1997) [J].
Granizo, JJ ;
Aguilar, L ;
Casal, J ;
García-Rey, C ;
Dal-Ré, R ;
Baquero, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (05) :767-773
[15]  
HOBAN D, 1998, 4 INT C MACR AZ STRE
[16]   Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999 [J].
Hoban, DJ ;
Doern, GV ;
Fluit, AC ;
Roussel-Delvallez, M ;
Jones, RN .
CLINICAL INFECTIOUS DISEASES, 2001, 32 :S81-S93
[17]   The activity of Levofloxacin and comparator agents against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999 and 2000 [J].
Jones, ME ;
Blosser-Middleton, RS ;
Critchley, IA ;
Thornsberry, C ;
Sahm, DF ;
Yamakita, J ;
Akasaki, M ;
Karlowsky, JA .
CHEMOTHERAPY, 2002, 48 (05) :232-237
[18]   COMMUNITY-ACQUIRED PNEUMONIA - ETIOLOGY, EPIDEMIOLOGY, AND TREATMENT [J].
MANDELL, LA .
CHEST, 1995, 108 (02) :S35-S42
[19]   EXTREMELY HIGH-INCIDENCE OF ANTIBIOTIC-RESISTANCE IN CLINICAL ISOLATES OF STREPTOCOCCUS-PNEUMONIAE IN HUNGARY [J].
MARTON, A ;
GULYAS, M ;
MUNOZ, R ;
TOMASZ, A .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (03) :542-548
[20]   The cost of treating community-acquired pneumonia [J].
Niederman, MS ;
McCombs, JS ;
Unger, AN ;
Kumar, A ;
Popovian, R .
CLINICAL THERAPEUTICS, 1998, 20 (04) :820-837